Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

0.3380 +0.0054 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Which stocks have an unusual volume on Monday?
Unusual volume stocks are being observed in Monday's session. 
Via Chartmill
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential. 
Via Benzinga
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
From Rallybio Corporation
Via Business Wire
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
From Rallybio Corporation
Via Business Wire
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
From Rallybio Corporation
Via Business Wire
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
From Rallybio Corporation
Via Business Wire
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
From Rallybio Corporation
Via Business Wire
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
From Rallybio Corporation
Via Business Wire
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
From Rallybio Corporation
Via Business Wire
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
From Rallybio Corporation
Via Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
From Rallybio Corporation
Via Business Wire
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.